and 3 rectal toxicities, respectively with no rectal fistula or ulcer at this time.
For high-risk and very high-risk prostate carcinoma, IMRT plus regional hyperthermia was feasible with acceptable toxicity, and further studies to assess the efficacy of this combined treatment are warranted. 
EP-1583 An endorectal balloon reduces patientreported GI toxicity in postop radiotherapy

Purpose or Objective
In dose-escalated radiotherapy (RT) of prostate cancer late rectal toxicity is one of the dose limiting factors. In primary RT, an endorectal balloon (RB) has been shown to reduce the dose to parts of rectum and anus, stabilize prostate position and may therefore be a means to improve therapeutic ratio. In postoperative radiotherapy the effect of RB is less well-known, in general a dose of <70 Gy is applied and therefore no clinical outcome data regarding the benefit of a RB is available. The aim of this retrospective study was to assess the patient-reported late rectal toxicity (GItox) 3, 12, and 24 months after RT in postoperative prostate cancer patients receiving a daily RB, compared to an earlier cohort, which was treated without RB.
Material and Methods
We identified all patients who received postoperative radiotherapy (66 Gy in 33 fractions) after radical prostatectomy, had no nodal or distant metastases and at least one follow-up visit. In those treated between 2008 and 2013, no RB was applied whereas between 2014 and 2016, a RB was routinely applied. All patients were followed with the same set of questionnaires and outpatient visits. Results where compared and analysed by Chi²-Test (SPSS 23.0).
Results
In total, 433 patients were retrieved, of whom 194 were treated with and 239 patients without RB. The patients were well balanced according initial NCCN risk and other confounding factors.
The maximum patient reported GItox in the first 2 years after RT was low: 75,5%, 20,8%, 3,7 %, 0 % reported no, grade 1 (G1), G2 and G3 GItox, respectively. The prevalence of rate of G1+ GItox was 16,5%, 15,1% and 18,0% at 3, 12, and 24 months, respectively. No GItox within 2 years occurred in 71,1% patients without RB versus 80,9% with RB. G1+ GItox was reported in 28,5% without RB and in 19,1% with RB. G2 GITox was reported by 13 (5,4%) patients without and by 3 (1,5%) with RB. These results are statistically significant at p<0,025. Purpose or Objective Dose escalation in prostate cancer trials showed an increased toxicity. Low alpha-beta ratio of prostate cancer make suitable to escalate dose by extreme hypofractionation. Stereotactic Body Radiation Therapy (SBRT) in prostate cancer is a novel precise strategy which allows delivering high doses per fraction with high accuracy to the prostatic gland in a low number of fractions. In order to evaluate the feasibility and toxicity of two regimens of hypofractionated stereotactic body radiation therapy self-reported quality of life (QOL) measures were obtained.
Material and Methods
Two prospective phase I-II studies were approved by our institutional review and ethics board. Inclusion criteria were: Trial1) T1-2N0M0, Gleason Score 6-7, PSA ≤ 20 ng/mL, and IPSS 0-7. Dose 85 GyEqD2. Trial 2) T3aN0M0 Gleason score 8 or less (N+risk<25%) and IPSS 0-12. Dose 87GyEqD2. Hormonal-therapy was prescribed according to risk classification. Image Guided RT with Cone Beam CT was mandatory. Dose SBRT was delivered at a prescribed planning target volume (PTV) 35 Gy in five fractions in 5 alternative days or 9 Gy after 60 Gy 2 Gy per fraction in 30 days, using with RapidArc VMAT, with 6 MV FFF photons. CTCAE v4.0 morbidity scores were used to assess toxicities. Health-related quality of life questionnaire was administered centrally by telephone interview before treatment and during follow-up (at 3, 6 and 12 months 
